Michael Newman

Michael Newman

Company: Decoy Biosystems

Job title: President & Chief Executive Officer

Seminars:

Speaker Q&A 8:50 am

Read more

day: Day One

Combination Systemic Therapy with a Multiple TLR Agonist Safely Eradicates Established Tumors with Induction of Innate and Adaptive Immunological Memory 8:25 am

Decoy Biosystems is developing a new and improved systemicallyadministered version of Coley’s Toxins (killed, non-pathogenic, Gramnegative bacteria) that exhibits single agent activity and also synergizes with approved agents to safely eradicate established, solid tumors with induction of innate and adaptive immunological memory. Decoy bacteria are also active as a single agent in pre-clinical models of…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.